T-cell receptor (TCR) translocations are a genetic hallmark of T-cell acute lymphoblastic leukemia and lead to juxtaposition of oncogene and TCR loci. Oncogene loci become involved in translocations because they are accessible to the V(D)J recombination machinery. Such accessibility is predicted at cryptic recombination signal sequence (cRSS) sites ('Type 1') as well as other sites that are subject to DNA double-strand breaks (DSBs) ('Type 2') during early stages of thymocyte development. As chromatin accessibility markers have not been analyzed in the context of TCR-associated translocations, various genetic and epigenetic determinants of LMO2, TAL1 and TLX1 translocation breakpoint (BP) sites and BP cluster regions (BCRs) were examined in human thymocytes to establish DSB proneness and heterogeneity of BP site involvement in TCR translocations. Our data show that DSBs in BCRs are primarily induced in the presence of a genetic element of sequence vulnerability (cRSSs, transposable elements), whereas breaks at single BP sites lacking such elements are more likely induced by chance or perhaps because of patient-specific genetic vulnerability. Vulnerability to obtain DSBs is increased by features that determine chromatin organization, such as methylation status and nucleosome occupancy, although at different levels at different BP sites.
INTRODUCTION

T-cell receptor (TCR) translocations are the most common chromosomal rearrangements seen in human T-cell acute lymphoblastic leukemia (T-ALL).
1,2 Two types of translocation mechanisms have been proposed based on the involvement of the V(D)J recombination machinery in TCR translocation formation and on the sequence composition at the breakpoint (BP) sites. 3 'Type 1' translocations are formed when recombinase activating gene (RAG) complexes erroneously target a cryptic recombination signal sequence (cRSS) in an oncogene as their substrate. 3 'Type 2' translocations occur when non-RAG-cRSS mediated DNA double-strand breaks (DSBs) in oncogene sequences are repaired within a V(D)J recombination post cleavage synaptic complex. 3 As a result, oncogene and TCR loci are juxtaposed, which leads to deregulation of oncogene expression. 4 These TCR translocations are considered to be the initial aberration in leukemogenesis. 4 It is clear that oncogenic transformation might not manifest at the exact stage in which the translocation occurred but that oncogenic transformations tend to occur at a later developmental stage, 5, 6 usually after acquisition of subsequent mutational hits. 7, 8 However, the involvement of TCR genes, (c)RSSs and the V(D)J recombination machinery in the formation of these translocations collectively reveal that these aberrations originate in the most immature thymocyte subsets. TCR translocations mostly involve TCRD (14q11) and TCRB (7q34) loci. 2, 9, 10 The LMO2, TAL1 and TLX1 oncogenes are the most frequent TCR translocation partners in pediatric T-ALL, representing B7%, 3% and 8% of T-ALL cases, respectively. 1, 2, 9 Translocation BPs in these oncogene loci are either localized in breakpoint cluster regions (BCRs) or at single BP sites. 4, 10, 11 Ex vivo and in silico analyses of BP site sequences revealed that LMO2 and TAL1 translocations are mostly 'Type 1' translocations, whereas TLX1-associated translocations are predominantly 'Type 2'. 4, 10, 12, 13 Occurrence of a particular translocation in T-ALL is determined by the selective pressure that results from the oncogenic effect of the translocation. The latter is subject to the actual position of the BP site within the oncogene locus and the type of TCR locus involved. 4, 6 However, this selective advantage through oncogenic activation does not explain why particular BP sites localized within the same oncogene region are recurrently involved in translocations, whereas others are not.
Examination of non-TCR-associated recurrent chromosome translocations shows that these translocation BP sites are flanked by sequences that possess particular sequence-specific features that render these sites prone to DSBs. The colocalization of chromatin structural elements with BCRs, such as in vivo topo II cleavage sites, DNase I hypersensitive sites, the lowest free energy (DG) level, high GC-content (guanine-cytosine-content) and repeat elements (transposable elements (TEs)), have all been implicated in various leukemias. [14] [15] [16] [17] [18] [19] The presence of a cRSS at BP sites is a genetic feature known to render DNA susceptible to DSB induction in 'Type 1' TCR translocations. Despite the fact that 'Type 2' translocations occur more often than 'Type 1' translocations, 6 ,10,12 it is still not known which sequence-specific features render 'Type 2' translocation BP sites prone to DSBs. 3 However, the frequency of occurrence of 'Type 2' translocations and the formation of BCRs at these sites would suggest that such determinants should indeed exist for 'Type 2' translocation BP sites.
Changes in the higher-order chromatin organization as caused by variation in chromatin structure correlate with the vulnerability of particular sites to obtain breaks. 14, 20 DNA methylation and nucleosome remodeling activity have been shown to influence access of DNA to DNA-modifying elements. 21, 22 Furthermore, methylated DNA is enriched in nucleosome-bound DNA. 23 These epigenetic factors have been identified at translocation BP sites and have been shown to coincide with localized proneness for DSB induction. 14, 24 Chromatin organization also plays an essential role in the physiological V(D)J recombination process. TCR recombination occurs at specific developmental stages and is regulated by the ability of RAG protein complexes to gain access to RSSs as their chromosomal substrate. 25 Different open chromatin markers (activating histone modifications, DNA hypomethylation, nuclease accessibility and germline transcription) appear to correlate with time and position of V(D)J recombination. This indicates the pivotal role for chromatin accessibility in this process. [25] [26] [27] [28] These chromatin accessibility markers have not yet been analyzed in the context of TCR-associated translocations, nor has this been determined in the context of pretranslocation formation in differentiating (precursor) T cells. We hypothesize that oncogene loci involved in TCR translocations must be accessible to elements of the V(D)J recombination machinery to enable erroneous DSB induction and repair that could lead to translocation formation. This accessibility is thought to be required at cRSS sites ('Type 1'), as well as at other sites that are subject to DSBs ('Type 2') during early stages of thymocyte development.
Here we studied whether genetic and epigenetic determinants at T-ALL-derived LMO2, TAL1 and TLX1 translocation BP sites render these sites prone to DSB induction, and consequently to TCR translocation formation. Our findings suggest that proneness for DSBs in BCR is primarily determined by a genetic element of sequence vulnerability that renders DNA susceptible for DSB induction and that DNA methylation and nucleosome occupancy at these sites influence their vulnerability to acquire DSBs.
RESULTS
LMO2, TAL1 and TLX1 T-ALL-associated BP regions BP sites/regions that were found to be associated in human T-ALL with TCR translocation junctions involving the LMO2, TAL1 and TLX1 loci were selected for this study 4, 6, 11, [29] [30] [31] (Supplementary Table 1 ). These particular oncogenes were chosen as they are the most common TCR translocation partners seen in T-ALL. 10 Criterion for inclusion of the oncogene BP sites/regions for further in silico and in vitro analysis was that they should be representing different types of BP regions based on (1) involvement of TCRD and TCRB locus translocations; (2) presence of 'Type 1' and 'Type 2' translocations and (3) distinct localization within the oncogene loci. This resulted in 9 representative BP regions (reflecting a total of 38 published BP sites). Distinction between BCRs (defined as more than two BP sites within a region of 50 bp while sharing a common translocation DSB type) and single BP sites was made (Figure 1 ). Two BCRs were identified upstream of LMO2 exon 1 (BCR 1 and BCR 2 ), and one BCR was identified upstream of both TAL1 and TLX1 exon 1.
10 BP sites in the LMO2 BCR 1 , TAL1 BCR and TLX1 UPN43 sites were found to be associated to a cRSS within maximally 10 bp distance, which is indicative of 'Type 1' translocation sites 10 ( Figure 1 and Supplementary Table 1 ). The other BP sites did not locate adjacent to a cRSS, which effectively qualifies them as 'Type 2' translocation sites ( Figure 1 and Supplementary Table 1 ). BCRs in all three loci appeared to be localized in the direct vicinity of the transcriptional starting site (TSS) of the oncogenes, irrespective of the presence of a cRSS, whereas single BP sites are generally located more remote from the TSS. ) . 4, 10, 12, 13 Gray and white boxes indicate coding regions and untranslated regions (UTRs), respectively (adapted from Larmonie et al. 10 ).
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Transcription of oncogene loci does not reflect accessibility for translocation Rearrangements commonly occur in regions of high transcriptional activity. 32, 33 As the majority of BP sites are localized in the direct vicinity of the oncogene TSS, one might assume that transcription activity could be rendering these sites prone for breaks. We have previously shown that LMO2 is exclusively expressed in the double-negative (DN) 1, 2, 3 and immature single-positive (ISP) stages of thymocyte development. 34 Furthermore, we showed that TAL1 and TLX1 are not expressed at any stage of thymocyte development 34 ( Supplementary  Figure 1) . One might argue that the LMO2 locus is transcribed and thus vulnerable for DSB inductions during the earliest stages of thymocyte development. Furthermore, the fact that the majority of TCR-LMO2 translocations involve the TCRD locus (Supplementary Table 1 ) suggests that translocation formations involving the LMO2 locus can primarily occur during the DN1 and DN2 stages, the stages of active TCRD locus rearrangement. 35 However, LMO2 expression in hematopoietic cells is driven by the proximal promoter, 36 whereas LMO2 BP sites are localized in the vicinity of the distal promoter (Figure 1 ). This and the fact that TLX1 and TAL1 are not expressed in thymocytes shows that active transcription of an oncogene is not a predictive factor for translocation proneness. More importantly, transcriptional activity of an entire locus does not reflect the actual accessibility of individual BP sites.
These findings imply that other levels of chromatin organization other than transcription-associated chromatin organization should be rendering oncogene BP sites vulnerable for DSB induction.
BP sites are mostly localized at sites and regions of high GC-content As transcription does not equal accessibility of individual BP sites, we focused on other factors of chromatin accessibility. Low free energy (DG) levels are required for unwinding double-strand DNA and facilitate protein-DNA interactions, thereby also enabling access of these sites to DNA-damaging agents. 14, 15 We studied the DG level of the LMO2, TAL1 and TLX1 loci, and determined the DG required to unwind double-strand DNA at each BP site based on the genomic composition of the different loci. This revealed that the BP sites did not occur in regions of the lowest DG levels (53.9-81.5 kcal mol À 1 ) in these oncogene loci (Supplementary Figure 2) . Even though the BP sites did localize at sites of relatively low DG levels compared with their respective flanking sequences (LMO2, TAL1 and TLX1 BCRs were within sites with DG levels of 92.72-99.16, 127.65-133.16 and 107.86-139.18 kcal mol À 1 , respectively), the levels were still higher than the lowest energy levels (Supplementary Figure 2 and Table 1 ). This indicates that DSB induction at the BP sites in LMO2, TAL1 and TLX1 is not primarily related to low DG levels. The observed DG levels between the different BP sites generally did not seem to differ much, thus making a correlation between DG levels and the formation of BPs at these sites less likely.
Regions of high GC-content have been suggested to correlate with DSB localization. 32, 37 As was anticipated, the LMO2, TAL1 and TLX1 loci indeed appeared to have an average GC-content of 46%, 53% and 51%, respectively, that is higher than the average GC-content of the total human genome (B41%) 38 ( Figure 2a ). For all analyzed BP sites, the GC-content (range B44-60%) at a scale of 1 kb flanking each BP site similarly exceeded the average human genome GC-content ( Figure 2a and Table 1 ). GC-content can be classified into five different isochors families (L1, L2, H1, H2 and H3) that are categorized by different GC levels as previously described. 39 We determined the GC level of the BP sequences and the Isochors family related to each BP sites by scanning the gene sequence using the EMBOSS Isochore program online (http://www.ebi.ac.uk/Tools/emboss/cpgplot/ index.html). Even though most individual BP sites did not appear to colocalize with peaks of very high GC-content (Figure 2b ), the localized GC-content at each BP site revealed that all BP regions analyzed were within areas with a GC-content substantially higher than the human genome average (Figures 2a  and b ). TAL1 BP P1/P5 and TLX1 BP T178 regions were localized with sequences associated with the H3 Isochore family (GCcontent 452%; Figure 2 ). The TAL1 BCR, LMO2 BCR 2 and BP UPN4395 regions and the TLX1 BCR and the BP UPN43 and BP T051 and N280 regions were associated with levels related to the H2 Isochore family (GC-content between 47 and 52%; Figure 2b and Table 1 ). The general localization of BP sites/regions in areas of high GC-content could imply a role for high GC-content and DNA instability that could result in region susceptibility for DSB induction. Although the precise mechanism involving high GC-content regions in DSB induction is not yet known, its association with recombination hot spots has been clearly documented. 18 No particular differences were observed between 'Type 1' and 'Type 2' BP sites, or BCR and single BP site occurrence and the GC-content at the respective sites. The TLX1 BCR and the TLX1 BP T178 are located within TE sequences Repeat elements such as TEs are located throughout the entire genome and have also been shown to be involved in genomic rearrangements. These TEs coincide with high GC-content regions. Particularly, the hypomethylation of CpGs at these sites is usually associated with transcription and retrotransposition of TEs, which is further associated with genetic instability and cancer. [16] [17] [18] [19] Figure 2. BP sites are associated with regions of high GC-content. (a) The average GC-content of the LMO2, TAL1 and TLX1 loci and BP sites (flanking region of 1 kb) were determined with the Gene Promoter Miner (GPMiner) online tool, 57 determined within a window of 100 nt, each time sliding 1 nt and represented relative to the average GC-content (B41%) of the human genome (dashed horizontal line). (b) Pattern of GC-content of LMO2, TAL1 and TLX1 loci using the Isochore program of the EMBOSS package with a sliding window size of 1000 bp. Arrowheads indicate the location of the BP sites. Positions are given relative to the TSS, as indicated with a bended arrow. Black and gray (untranslated region (UTR)) boxes represent exons in that region. The average GC-content (B41%) of the human genome 38 is indicated with a dashed horizontal line; x indicates which BP site has a cRSS.
(Epi)genetics at TCR translocation breakpoint sites NSD Larmonie et al As TEs are involved in DSB proneness and genome instability, 38, 40 we determined whether the different BP sites/regions contain TE sequences. Whereas the LMO2 BCR 1 was located in the vicinity (within 20 nt) of a SINE2 element (Figure 3) , none of the other LMO2 or TAL1 BP sites were located in the vicinity of or within a TE. Two of the four TLX1 BP sites did localize within a TE: the TLX1 BCR overlapped with an ERV1 sequence and TLX1 T178 BP site was located within a SINE (MIR) sequence (Figure 3 ). Both SINE and ERV sequences have been shown to be associated with particular translocation BP sites. 17, 19 BP sites are predominantly unmethylated during thymocyte development Unmethylated DNA reflects open chromatin [41] [42] [43] that in turn correlates with DSB proneness. 44 We therefore evaluated the methylation status of the oncogene translocation BP sites to determine the role of DNA methylation in rendering these sites vulnerable to DSB induction.
As only cytosine bases in the context of CpG can be methylated in eukaryotes, 43 we first determined the CpG composition of the different oncogene loci. The LMO2 BP sites/regions were all localized in relatively CpG-poor areas (Supplementary Figure 3) . The TAL1 P1 and P5 BP sites did localize within a CpG island, although at the less CpG-dense tail of the CpG island, whereas the TAL1 BCR localized within a CpG-rich region (Supplementary Figure 3) . All TLX1 BP sites were also located in relatively CpG-rich regions, whereas the TLX1 BCR localized in one of the five CpG islands identified in the TLX1 locus (Supplementary Figure 3) . Of the three cRSSs included in our studies, only the TAL1 BCR carried a CpG in the heptamer (Figure 4) . Methylation within the heptamer of a (c)RSS could influence RAG activity. 45 CpG-rich regions have been shown to correlate with activation-induced cytidine deaminase (AICDA or AID)-induced DSBs. However, as AID is not expressed in T cells contrary to B cells, we did not address the involvement of a CpG-AID DSB induction mechanism in these studies. 46 Next, we analyzed the methylation status of CpGs flanking the LMO2, TAL1 and TLX1 BP sites/regions during differentiation by means of bisulfite sequencing (Figure 4) . The CpGs at the LMO2 BCR 1 were B98% methylated during thymocyte development ( Figure 4 and Table 2 ), whereas all CpGs surrounding the BCR 2 site were unmethylated in all thymocyte stages. CpGs associated with the LMO2 UPN4395 BP site were also predominantly (B72%) methylated; certain CpGs varied in methylation status per thymocytic differentiation stage, although no significant difference in methylation status was observed (P ¼ 0.09) between stages ( Figure 4 and Table 2 ). In 2 out of 3 LMO2 BP regions, methylated CpG sites are observed in the flanking areas, but the true impact of this is still elusive given the clear lack of CpG islands around these BP regions. Overall, the methylation status of CpGs at the BP sites did not differ between different thymocyte developmental stages, with the exception of the TLX1 T178 region (Po0.00). The latter was the result of a change in methylation status of one CpG, shifting from unmethylated in the DN stages of thymocyte development to methylated in the subsequent stages. The CpGs at the TAL1 BCR, P1 and P5 BP sites were mainly unmethylated; methylation varied during development with an average of B13 and B8%, but differences were not significant (P ¼ 0.16 and P ¼ 0.75, respectively; Figure 4 and Table 2 ). The CpG Figure 3 . TE mapping at BP sites. The LMO2, TAL1 and TLX1 loci were screened for the presence of transposon-derived repetitive elements (TEs) using the CENSOR tool against the Repbase database (http://www.girinst.org/repbase). 59 The different TE subclasses are shown for each locus. Blocks represent the four classes of TE: DNA (DNA transposons), SINE (short interspersed elements), LINE (long interspersed elements) and LTR (LTR retrotransposons); x indicates which BP site has a cRSS. * indicates other type of TE.
in the heptamer of the TAL1 BCR cRSS was also mainly unmethylated, suggesting that RAG activity is not hampered by methylation at this BCR. The TLX1 BCR region appeared hypomethylated during all stages of thymocyte development. The UPN43 BP site showed heterogeneity in methylation status of the CpGs at each stage of thymocyte development, but again no significant difference in overall methylation status was observed between the subsets (P ¼ 0.95; Figure 4 and Table 2 ). The CpGs associated with TLX1 BP sites T178, T051 and N280 were mainly unmethylated, with only an average of 3.8% and 1.7% of BP siteassociated CpGs methylated, respectively ( Figure 4 and Table 2 ). Of all the regions analyzed, o1.5% of the sequences were methylated, either because of the presence of low numbers of CpGs in this region, or because of the fact that the region was primarily unmethylated (Table 2 ). It is noteworthy that both the TLX1 BCR and the T178 BP site were associated with unmethylated TE sequences.
Collectively, the methylation analysis data show that the majority of CpGs associated with the BP sites are unmethylated during thymocyte development, thus suggesting that the involved BP regions are associated with a generally more open chromatin structure and that the accessibility of the regions is not affected by a high percentage of methylated CpGs. Most LMO2 and TLX1 BP sites are nucleosome depleted during all stages of thymocyte development To assess whether the methylation status of the BP sites corresponds with nucleosome formation at these sites, 21, 22 we then analyzed accessibility of the BP sites at the nucleosomal level by means of the FAIRE (formaldehyde-assisted isolation of regulatory elements) assay. 47, 48 First, we compared the nucleosomal levels between BP sites within the same locus in order to determine whether a differential accessibility to the different BP sites could explain the difference in BP site involvement in TCR translocations. The LMO2 BCR 1 and BCR 2 sites were slightly enriched in the FAIRE samples, but at significantly lower levels than glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The LMO2 UPN4395 BP site was not at all enriched in any of the samples, suggesting that this was a nucleosome-bound DNA region during all developmental stages ( Figure 5 ). Neither the TAL1 BCR nor the TLX1 BCR was enriched in any of the thymic fractions ( Figure 5 ). In an attempt to understand the interlocus differences in oncogene involvement, we compared the accessibility of the different oncogene BCRs with each other. Compared with TAL1 BCR and TLX1 BCR, a significantly higher enrichment (Po0.001) was observed for the LMO2 BCR 1 in all thymic fractions, which is indicative of a more open configuration at the LMO2 Figure 4 . DNA methylation analysis of oncogene BP sites during thymocyte development. Methylation status of CpGs in sequences flanking B250 bp of the LMO2, TAL1 and TLX1 BP sites were analyzed by bisulfite sequencing. DNA was isolated from sorted thymocyte subsets of pooled human thymus samples of five individuals. The average methylation status of CpGs is shown based on sequences collected from 5 to 12 colonies. Sequence analysis was done with the QUMA methylation analysis tool (http://quma.cdb.riken.jp/). cRSS sequences at the LMO2 BCR, TAL1 BCR and TLX1 UPNC43 BP site are shown in the gray boxes. CpGs in the sequences are underlined in bold. Only the CpG at the heptamer influences reactivity of RAG upon methylation. Only the TAL1 BCR cRSS has a CpG in the heptamer sequence of the cRSS. Methylated CpG (K); unmethylated CpG (J); differentially filled circles: partly methylated CpGs (in different clones). ND, not determined because of insufficient material or lack of reliable sequences. All these samples have a standard error of zero.
(Epi)genetics at TCR translocation breakpoint sites NSD Larmonie et al BCR 1 . Conversely, the remaining TLX1 BP sites were enriched in all thymic fractions ( Figure 5 ). Enrichment of the TLX1 T178 BP site was observed to be significantly (Po0.001) higher than enrichment of GAPDH in all fractions. The TLX1 UPN43 BP site was enriched in the single-positive (SP) fraction at comparable levels to GAPDH ( Figure 5 ). No significant differences were seen in enrichment levels between different thymic fractions for most BP sites, with the exception of LMO2 UPN4395. However, these observed values were below threshold levels. This suggests that the state of nucleosome occupancy at the different BP sites is overall stable during thymocyte development ( Figure 5) .
Collectively, the FAIRE data show that the TLX1 oncogene BP sites are most accessible during thymic development, whereas the LMO2 UPN4395 BP site is largely inaccessible. Furthermore, the TAL1 BCR and TLX1 BCR are less accessible than the LMO2 BCRs.
DISCUSSION
Locus vulnerability is one of many conditions hypothesized to be an essential requirement for DSB induction as the first step in translocation formation. Transcriptional activity could be indicative of locus accessibility, 32 whereas a mutational bias has been shown toward regions of high transcriptional activity. 32, 33, 49 However, the absence of (localized) transcriptional activity of the LMO2, TAL1 and TLX1 oncogenes in thymocytes demonstrates that in these loci transcriptional activity is not a prerequisite in the vulnerability to attain DSBs, even though BCRs frequently do localize in the vicinity of the oncogene TSSs. This suggests that factors other than transcription are involved in rendering these sites vulnerable for DSB induction. Unlike previously shown for other types of translocations, 14 LMO2, TAL1 and TLX1 BP sites did not localize with the lowest DG levels observed for each of the oncogene loci. Based on our observations we therefore conclude that there is a limited role for helical instability and replication initiation as the cause for DSB vulnerability at these particular sites. 32, 50 Furthermore, although most BP sites do not colocalize with peaks of very high GC-content, 8 of the 11 BP sites were at sites with a GC-content above the average human content. Neither regional nor local GC-content elucidates the heterogeneity of BP site involvement, but the high GC-content of the BP site sequences would suggest a contribution of GC composition to genome instability at these sites.
When considering LMO2 BPs, no sequence-specific features of DSB vulnerability were identified at the LMO2 UPN4395 and BCR 2 'Type 2' sites, which is contrary to the LMO2 BCR 1 'Type 1' cRSS site. Theoretically, the difference in LMO2 UPN4395 and BCR 2 involvement in T-ALL could be associated with a differential accessibility of these sites during thymocyte development. However, the fact that the LMO2 UPN4395 translocation resulted in an extremely high expression of LMO2 as compared with translocations involving the LMO2 BCRs does not fit with the rare Figure 5 . Relative enrichment of nucleosome-free BP regions in TAL1, LMO2 and TLX1 during different stages of thymocyte development. Thymocytes were sorted and several thymic subsets were pooled to obtain large enough cell numbers per experiment in the following manner: DN fraction (DN1, DN2 and DN3 subsets), ISP/DP fraction (ISP, DP CD3 À , and CD DP3 þ subsets) and SP fraction (SP CD4 þ and SP CD8 þ subsets). DNA was isolated by means of FAIRE and enrichment of BP sites was determined by real-time quantitative-PCR (RQ-PCR) using primers and probes that were designed to target BP regions of o100 bp. FAIRE enrichment was calculated according to the Pfaffl method. 61 Enrichment was corrected for the signal from the epigenetically silenced CD19 gene in thymocytes. 20 Two-way analysis of variance (ANOVA) analysis was carried out to determine differences in relative enrichment between BP sites in the thymic fractions.
þ , K and * denote significant differences between BP sites and GAPDH, between BP sites within the same locus, and between BCRs of different loci, respectively. Dashed lines indicate equal levels of enrichment detected with CD19 and BP sites.
KKK and ***Po0.001;
KK
Po0.01; x indicates which BP site has a cRSS.
(Epi)genetics at TCR translocation breakpoint sites NSD Larmonie et al occurrence of the LMO2 UPN4395. 4 This would suggest that sites that are associated with a less open chromatin are less likely to be subject to DSB induction. The LMO2 BCR 1 is more frequently involved in translocations than the LMO2 BCR 2 that suggests that the cRSS at BCR 1 could be preferentially targeted despite the higher accessibility of other regions in the vicinity. Differential accessibility was also observed between the LMO2 BCR 1 and the TAL1 BCR, as nucleosome depletion analysis proved the LMO2 BCR 1 to be significantly more accessible than the TAL1 BCR. This may contribute to the higher frequency of TCR-LMO2 translocations than TCR-TAL1 translocations (7% vs 3%, respectively) observed in T-ALL. Chromatin immunoprecipitation analyses of particular histone marks at the involved sites should shed more light on these differences in future studies.
With respect to TLX1 translocations, these are mainly known to involve the TLX1 BCR and are typically 'Type 2' translocations. The majority of the TLX1 BP sites were localized within regions of unmethylated CpGs. This contradicts previous assumptions regarding the exclusivity of demethylation of the TLX1 BCR (promoter region) upon TLX1 expression in T-ALL. 51 The association of the TLX1 BCR with an unmethylated ERV1 repeat in thymocytes is notable, as the unmethylated status of a TE is associated with genetic instability and cancers. 52 This association might well explain DSB proneness for involvement in 'Type 2' translocations at the TLX1 BCR. The differences seen between the 'Type 2' LMO2 BCR 2 and TLX1 BCR involvement in T-ALL substantiate our notion that the presence of a genomic feature of vulnerability could substantially increase the chance for DSB induction at that particular site. Unexpectedly, nucleosome depletion analysis showed that the TLX1 BCR was not nucleosome depleted, whereas the other TLX1 BP sites were enriched at different levels. The cRSS-associated TLX1 UPN43 and TE-associated TLX1 T178 BP sites were located in primarily unmethylated, nucleosome-depleted sites, suggesting that these sites could be highly prone to DSBs. However, involvement of the UPN43 and T178 BP sites in TCR translocations is not comparable to the TLX1 BCR involvement in T-ALL. Surprisingly, the TLX1 T051 and N280 BP sites were not significantly enriched in the FAIRE assay, despite their occurrence within close vicinity of each other. This difference in involvement of the TLX1 BCR compared with the other TLX1 BP sites in T-ALL could be attributed to the location of the BP site in relation to the oncogene locus (5 0 or 3 0 end) or the TCR locus involved that might also affect post-translocation oncogenic effect. 4, 11 Based on the observed stability of the oncogene chromatin accessibility during thymocyte development, there does not seem to be a particular window of opportunity from the perspective of the oncogene that would explain locus involvement in TCRD or TCRB translocations. TCR gene involvement in TCR translocations suggests that the TCR translocation process must occur at the early stages of thymocyte development, the phase in which the TCR loci are accessible to RAG proteins for recombination. 25, 27, 35 It can thus be deduced that the window of opportunity for TCR translocation formation is primarily determined by the phase of TCR recombination rather than the relatively stable accessibility of the oncogene BP sites. We therefore conclude that other conditions involved in translocation formation, such as nuclear proximity of the loci, may eventually shed more light on the differential oncogene involvement in TCRD and TCRB translocations in T-ALL.
Based on the observed heterogeneity in genetic and epigenetic signatures at each BP site in our data set, we cannot clearly decipher one single mechanism involved in rendering BP sites prone to DSB induction as a prerequisite for TCR translocation formation. Our data clearly show that there is not one single factor or unifying mechanism that renders BP sites prone to DSB induction, which in our view implies that there are multiple ways to arrive at the same end point of DSB induction. A more extended analysis, including a larger set of BP regions/sites and for example a comprehensive analysis of histone marks, could perhaps provide more insight into the dominant mechanisms involved in driving induction of these DSBs in the future.
In summary, we argue that sequence-specific features that render DNA susceptible for DSB induction together with the methylation status and nucleosome occupancy of BP sites influence proneness for BP sites to obtain DSBs, although with different contributions per BP site. A preference for induction of DSB by RAG via 'Type 1' translocation is observed, as cRSS BCRs tend to be more frequently involved in TCR translocations than sites in the vicinity with an open chromatin conformation but no genetic vulnerability features. We further hypothesize that DSBs are more likely to occur if a genetic element of vulnerability is present at the BP site. This would even be true if the site is associated with characteristics of less open chromatin. This idea is substantiated by the finding that the TLX1 BCR is associated with a hypomethylated TE that could be the potential cause of genome instability at this site while this site is nucleosome bound. We do realize that the eventual selective advantage acquired by oncogene deregulation upon translocation ultimately determines the frequency of oncogene involvement in TCR translocations in T-ALL. 4, 53 In addition, the location of the BP within the oncogene locus also affects the level of oncogenic activation, 4 and thus the occurrence of a BP site in T-ALL. This implies that other highly frequent DSBs might not become apparent if no selective advantage is induced through oncogene deregulation. Based on our findings we conclude that DSBs in BCRs are primarily induced in the presence of a genetic element of sequence vulnerability (cRSSs, TE), whereas breaks at single BP sites lacking such elements are more likely induced by chance or perhaps because of patient-specific genetic vulnerability. Susceptibility to obtain DSBs is increased by features that determine chromatin organization (methylation status, nucleosome occupancy), although at different levels at different BP sites (see also Table 1 ).
MATERIALS AND METHODS
Human material
Thymocyte subsets were sorted from the thymi of immunologically healthy children undergoing cardiac surgery. The thymocyte samples of these children were obtained with the consent of their parents (Institutional Review Board-approved protocol hmPOO 94-03). Thymocytes of five different donors with ages ranging between 1 week and 6 years were pooled for sorting on a FACSAria sorter (BD Biosciences, San Jose, CA, USA), as previously described. 35 Real-time quantitative-PCR analysis RNA from thymocyte subsets was reverse transcribed into complementary DNA and real-time quantitative-PCR was performed as described previously 54, 55 using an Applied Biosystems 7000 PCR machine (Applied Biosystems, Foster City, CA ,USA). Specific primer probe sets were used to quantify GAPDH (Applied Biosystems) and CD19, 56 following normalization to ABL. 35 Previously published data on LMO2, TAL1 and TLX1 oncogene expression 34 in thymocyte subsets are shown in Supplementary Figure 1 .
In silico analyses of sequence-specific features LMO2 (ENST00000257818), TAL1 (ENST00000294339) and TLX1 (ENST 00000370196) genomic sequences were used as annotated by Ensembl (http://www.ensembl.org/index.html). Positions of TSSs were used as given by the University of California, Santa Cruz (UCSC) database (http:// genome.ucsc.edu). The GC-content of oncogene loci was determined using the Gene Promoter Miner (GPMiner) online tool 57 and determined within a window of 100 nt, each time sliding 1 nt. The CpG content of oncogene loci was determined with the CpG island extraction algorithm online tool (http://www.cpgislands.com). 58 The search criteria used were: GC-content X55%, observed CpG/expected CpG X0.65 and length 500 bp. 58 The genomic DNA sequences used for GC-content analysis started and ended at the most upstream and downstream BP sites identified for each (Epi)genetics at TCR translocation breakpoint sites NSD Larmonie et al particular oncogene with a flanking region of B1 kb. The CpG island extraction algorithm online tool only displays the GC-content of CpG islands. In light of this, the average GC-content of the loci (plus 1 kb directly flanking each individual BP site) was analyzed using the EMBOSS Isochore program online (http://www.ebi.ac.uk/Tools/emboss/cpgplot/ index.html) within a window of 1000 nt, each time shifting 1 nt. The free energy level (DG, kcal mol À 1 ) of BP sites was determined using the WEB-THERMODYN tool (www.gsa.buffalo.edu/dna/dk/WEBTHERMODYN). Sequences of B500 bp flanking the BCR and BP sites were screened for the presence of repetitive elements using the Repbase database (http:// www.girinst.org/repbase) in the CENSOR tool. 59 Bisulfite sequencing-based methylation analysis DNA from different sorted thymocyte subsets was isolated according to the Qiagen DNA isolation kit (Qiagen, Valencia, CA, USA) as per the manufacturer's protocol. Bisulfite conversion of DNA was conducted using the EpiTect Bisulfite Kit (Qiagen) according to the manufacturer's protocol. Bisulfite sequencing primers were designed with the MethPrimer design tool (http://www.urogene.org/methprimer/index1.html; Supplementary Table 2 ) and tested with the EpiTect Control DNAs kit (Qiagen). Amplification products were purified with the QIAquick PCR Purification Kit (Qiagen) and cloned into the p-GEM T-easy vector (Promega, Madison, WI, USA). Subsequently, vectors were transformed into DH5a (Invitrogen, Carlsbad, CA, USA)-competent cells and selected for ampicillin (Sigma-Aldrich, St Louis, MO, USA) resistance. A colony PCR was performed in order to identify positive colonies, followed by sequencing of the positive amplicons (Applied Biosystems). Sequences were analyzed with the QUantification tool for Methylation Analysis (QUMA, http://quma. cdb.riken.jp/). 60 The methylation status of the different BP sites was determined on 5-12 colonies for each studied state of thymocyte development.
FAIRE assay
FAIRE can efficiently isolate nucleosome-depleted genomic regions, including TSS and regulatory elements. 47 As FAIRE requires a substantial number of cells, pooled thymocyte fractions had to be used for DNA isolation, namely DN (DN1, DN2 and DN3 thymocytes), ISP/double-positive (DP) (ISP, DP CD3 À , DP CD3 þ ) and SP fractions (SP CD4 þ , SP CD8 þ ). Thymocytes were resuspended in RPMI-1640 (BioWhittaker/Lonza, Basel, Switzerland) at room temperature. Two aliquots of the same cell number were prepared for each thymocyte fraction. One aliquot was crosslinked with 1% formaldehyde (final concentration) for 10 min at room temperature, whereas the second aliquot was left untreated. After incubation, 1 M glycine was added. Cells were put on ice for 1 min to stop the crosslinking reaction. Both aliquots were treated identically following crosslinking. The pellet was resuspended and washed in phosphate-buffered saline (4 1C) after the cells were spun down. Cells were subsequently resuspended in a freshly prepared cell lysis buffer (10 mM Tris, pH 8.0, 10 mM NaCl, 0.2% NP-40 (20%), 10 mM sodium butyrate (Sigma-Aldrich) and 1 Â Complete Protease Inhibitors (Roche, Penzberg, Germany)) and incubated for 10 min on ice. After incubation and centrifugation (4 1C), nuclei were lysed in ice-cold lysis buffer (50 mM Tris, pH 8.0, 10 mM EDTA, 1% SDS, 10 mM sodium butyrate and 1 Â Complete Protease Inhibitors) for 10 min. Following this, chromatin immunoprecipitation dilution buffer (0.01% SDS, 1.1% TX-100, 1.2 mM EDTA, 16.7 mM Tris-HCL, pH 8, 167 mM NaCl and H 2 O) was added and samples were sonicated 10-20 times (15 s on and 45 s off; amplitude 6) on ice. Phenol-chloroform (Sigma-Aldrich) extraction was done after sonication (without de-crosslinking). The DNA was subsequently precipitated and washed with 70% ethanol and the pellet was air dried and resuspended in 10 mM Tris. Samples were used for real-time quantitative-PCR analysis using primers and TaqMan probes designed to identify DNA fragments o100 bp at different BP sites with high level of specificity (Supplementary Table 3 ). FAIRE enrichment was calculated using the Pfaffl method. 61 First, the efficiency (E) of each primer probe set was determined according to the formula: E ¼ 10 Relative enrichment was calculated using the following formula: relative enrichment ¼ E target À Á DCttarget = E reference gene À Á DCtreference gene . 61 The TSS site of the epigenetically silenced CD19 gene 20 was used as reference gene.
Statistical analysis
Average methylation of BP regions was calculated based on the average methylation of each CpG per sequence strand. Significant differences in methylation status between subsets were determined based on the methylation status of the CpGs per sequence length analyzed for each BP region, using the Kruskal-Wallis Test. FAIRE enrichment was expressed as the mean of values from two biological replicates. Enrichment between GAPDH and the different BP sites, as well as between different thymic subgroups for each BP site, was compared using two-way analysis of variance test combined with Bonferroni post-test. All statistical analyses were performed using GraphPad Prism (V5.0 GraphPad Software Inc., San Diego, CA, USA).
